Navigation Links
Lenalidomide Gives New Hope To Chronic Lymphocytic Leukemia Patients

According to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), patients treated with lenalidomide// for relapsed chronic lymphocytic leukemia (CLL) or diseases that no longer responded to chemotherapy have experienced a major response to the therapy. The results of this study were published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.



Source-Eurekalert
SR
'"/>




Page: 1

Related medicine news :

1. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
2. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
3. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
4. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
5. US Doctors Association Gives away $110,000 To NGO’
6. Woman In Coma Gives Birth To Daughter
7. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
8. New Eye Surgery Gives Hope To Short-Sighted
9. Jharkhand Gives Health industry status
10. WHO Gives Its Approval For Bird Flu Test Kit
11. FDA Gives Its Approval For Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/20/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh has posted a new publication this ... generation is a time like no other and society needs to understand the only way ... does not want to sound like an old bible beater because religion has a bad ...
(Date:1/20/2017)... ... 2017 , ... Doctor C LLC, a company based out of Arizona that ... continue the marketing and distribution of its product, The Right C. , The Right ... absorption than traditional vitamin C supplements. At the trade show, Doctor C had the ...
(Date:1/20/2017)... ... 20, 2017 , ... Lice Troopers, the lice removal company based in South ... since the holiday season. , “It happens every year around this time,” says ... taking photos, which is the head-to-head gateway that lice need to spread.” , As ...
(Date:1/20/2017)... FL (PRWEB) , ... January 20, 2017 , ... International ... of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show in ... bodybuilder and nutritional scientist who was determined to create a line of products that ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
(Date:1/19/2017)... , January 19, 2017 ... Option to Address Motor Symptoms and Motor Complications ... ...      (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO) ... , European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late ...
(Date:1/19/2017)... The Global Therapy Partnering Terms and Agreements ... deals and agreements entered into by the world,s leading ... Top deals by value - Deals listed by company ... The report provides understanding and access to the partnering ... healthcare companies. The report provides an analysis of ...
Breaking Medicine Technology: